STP-061002 is under clinical development by ST Pharm and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According to GlobalData, Phase I drugs for Kidney Cancer (Renal Cell Cancer) have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how STP-061002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STP-061002 overview
STP-061002 is under development for the treatment of solid tumors including colorectal cancer, non-small cell lung cancer, gastric cancer, renal cell cancer and hepatocellular carcinoma. The drug candidate is administered through oral route in the form of capsule. It acts by targeting tankyrase (TNKS).
See Also:
ST Pharm overview
ST Pharm offers manufacturing services for active pharmaceutical ingredients and intermediates. It provides nucleoside-based active pharmaceuticals in various antiviral drug applications. ST Pharm’s pipeline products include STP0404 treats HIV and AIDS, STP1002 treats cancer; STP2104 and STP2130 treats COVID-19; NASH and oral heparin and influenza virus. The company works in collaboration with ASAN Medical Center, Emory University and Konkuk University, among others. ST Pharm is headquartered in Siheung, Seoul, South Korea.
For a complete picture of STP-061002’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
